Stockscreener 앱 받기
20.51
20.79%
3.53
시간 외 거래:
20.40
-0.11
-0.54%
전일 마감가:
$16.98
열려 있는:
$17.34
하루 거래량:
571.72K
Relative Volume:
3.07
시가총액:
$863.68M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+28.19%
1개월 성능:
+27.47%
6개월 성능:
+194.68%
1년 성능:
+0.00%
1일 변동 폭
$17.03
$20.51
1주일 범위
$16.11
$20.51
52주 변동 폭
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
20.51 | 715.03M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Can Zenas BioPharma Inc. hit a new high this monthMarket Risk Analysis & Growth Oriented Trade Recommendations - Newser
Pattern recognition hints at Zenas BioPharma Inc. upsideInsider Buying & Reliable Breakout Forecasts - Newser
Insiders Rewarded With US$1.5m Addition To Investment As Zenas BioPharma Stock Hits US$864m - simplywall.st
Can Zenas BioPharma Inc. reach all time highs this yearPortfolio Return Report & Detailed Earnings Play Strategies - خودرو بانک
Can Zenas BioPharma Inc. deliver consistent dividendsJuly 2025 Summary & Expert-Curated Trade Recommendations - خودرو بانک
Nuveen LLC Buys Shares of 31,626 Zenas BioPharma, Inc. $ZBIO - Defense World
Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
Wedbush Has Bullish Outlook for Zenas BioPharma Q3 Earnings - Defense World
Quantitative breakdown of Zenas BioPharma Inc. recent moveDip Buying & Fast Gain Swing Trade Alerts - Newser
Is Zenas BioPharma Inc.’s growth already priced inEarnings Trend Report & Daily Profit Focused Screening - خودرو بانک
What machine learning models say about Zenas BioPharma Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - Newser
Block Trades: What is Zenas BioPharma Inc.’s TAM (Total Addressable Market)July 2025 Recap & High Yield Stock Recommendations - خودرو بانک
Using data models to predict Zenas BioPharma Inc. stock movementPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Is Zenas BioPharma Inc. meeting your algorithmic filter criteriaJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Newser
Using data filters to optimize entry into Zenas BioPharma Inc.2025 Institutional Moves & Consistent Growth Stock Picks - Newser
Measuring Zenas BioPharma Inc.’s beta against major indicesJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
What MACD and RSI say about Zenas BioPharma Inc.Portfolio Growth Summary & Daily Growth Stock Tips - Newser
Real time breakdown of Zenas BioPharma Inc. stock performanceRecession Risk & Precise Buy Zone Tips - Newser
Royalty Pharma's Strategic Position in the Biopharma Royalty Space - AInvest
Using fundamentals and technicals on Zenas BioPharma Inc.July 2025 Outlook & Growth Oriented Trade Recommendations - Newser
Technical signs of recovery in Zenas BioPharma Inc.Weekly Stock Report & Weekly Setup with High ROI Potential - Newser
Is Zenas BioPharma Inc. still a buy after recent gainsWeekly Investment Report & Reliable Entry Point Trade Alerts - beatles.ru
How moving averages guide Zenas BioPharma Inc. tradingWeekly Trade Recap & Precise Trade Entry Recommendations - Newser
How institutional ownership impacts Zenas BioPharma Inc. stockShare Buyback & Free Verified High Yield Trade Plans - Newser
Chart based exit strategy for Zenas BioPharma Inc.Weekly Market Report & Weekly Top Gainers Alerts - Newser
Will Zenas BioPharma Inc. price bounce be sustainable2025 Fundamental Recap & Accurate Entry/Exit Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis toolsGap Down & Community Driven Trade Alerts - Newser
What’s the RSI of Zenas BioPharma Inc. stock2025 Geopolitical Influence & Verified Swing Trading Watchlists - خودرو بانک
Is Zenas BioPharma Inc. stock overvalued or fairly pricedJuly 2025 Catalysts & Short-Term Swing Trade Alerts - خودرو بانک
Is Zenas BioPharma Inc. trading at a discountJuly 2025 Institutional & Entry Point Confirmation Signals - خودرو بانک
Zenas Biopharma shares fall 2.28% intraday as Royalty Pharma announces $2.0 billion offering. - AInvest
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential - TipRanks
Trend analysis for Zenas BioPharma Inc. this weekJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
What institutional flow reveals about Zenas BioPharma Inc.2025 Earnings Surprises & Fast Momentum Entry Tips - Newser
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Published on: 2025-09-03 01:34:16 - Newser
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Tick level data insight on Zenas BioPharma Inc. volatility2025 Momentum Check & Expert Curated Trade Ideas - Newser
Sasol Limited shares rise 2.89% intraday after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Lead Plaintiff Appointed in Zenas BioPharma Class Action — Here’s How You Can Recover Your Losses - TradingView
Beone Medicines Ltd. shares rise 8.81% premarket after Royalty Pharma and Zenas BioPharma enter into a $300 million funding agreement. - AInvest
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Bolt Projects Holdings, Inc. shares rise 1.54% premarket after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Zenas BioPharma Secures $300M Funding for Obexelimab - TipRanks
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):